Ovarian Cancer

                    The text on this page has been created from Hansard archive content, it may contain typographical errors.
                

To ask the Secretary of State for Health what guidance his Department has given to NHS trusts on the use of Taxol combination treatments in the treatment of ovarian cancer. [34599]

Taxol is a drug licensed by the Medicines Control Agency for use in treating widespread cancer of the ovary or metastatic breast cancer where standard treatment regimes have failed. A clinical trial for first-line treatment of widespread breast cancer by Taxol in combination with other drugs is currently in progress. As with any other drug, it is a matter for individual clinicians, in discussion with their patients, to recommend a treatment regime which will be best for their patients. Guidance on clinical management of ovarian cancer was produced by the Standing Medical Advisory Committee and was published in November 1991.

To ask the Secretary of State for Health how many women in the Warrington North constituency were diagnosed as having ovarian cancer in each of the years 1992 to 1997. [34600]

Figures for Warrington North are not available separately. The latest available data for Warrington residents are set out in the tables, and relate to the five-year period 1990–1994:

Warrington residents 1990–1994: number of ovarian tumours
Age	Number
0–4	—
5–9	—
10–14	—
15–19	—
20–24	—
25–29	—
30–34	—
35–39	1
40–44	5
45–49	6

Warrington residents 1990–1994: number of ovarian tumours
Age	Number
50–54	12
55–59	12
60–64	7
65–69	14
70–74	12
75–79	14
80–84	4
85 plus	4
all ages	91

Warrington residents 1990–1994: age specific incidence rates per 100,000
Age	Rate
0–4	—
5–9	—
10–14	—
15–19	—
20–24	—
25–29	—
30–34	—
35–39	3.2
40–44	15.2
45–49	19.4
50–54	44.3
55–59	51.0
60–64	31.2
65–69	65.9
70–74	61.3
75–79	89.2
80–84	35.0
85 plus	44.0
all ages	19.3

Source

Merseyside and Cheshire Cancer Registry, March 1998.

Volume 308: debated on Tuesday 17 March 1998